Literature DB >> 6794883

Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes.

P J Kasvinsky, R J Fletterick, N B Madsen.   

Abstract

Synergistic regulation of glycogen phosphorylase a by the competitive inhibitors glucose and caffeine in vitro indicates a possible physiological role for the negative effector site which binds caffeine (nucleoside site). In intact viable hepatocytes glucose promotes the phosphorylase a to be conversion by phosphorylase phosphatase. This conversion is considered to be a necessary prelude to the activation of glycogen synthase by phosphatase and of importance in hepatic regulation of glucose homeostasis. The effects of glucose and(or) caffeine on the conversion of phosphorylase a to b and synthase b to a were studied. Assays of phosphorylase a were used which limited synergistic inhibition (in the assay) by these ligands. Such an approach is necessary to achieve an accurate measure of phosphatase activity in the viable hepatocyte when the combination of ligands is used. The data indicate that in the presence of caffeine and glucose together, the rate of loss of phosphorylase a is significantly increased (1.7-fold) over that in the presence of glucose alone. Phosphorylase phosphatase is activated. The sequential activation of glycogen synthase was also accelerated in the presence of both ligands. The results are consistent with an in vivo function for the nucleoside site, similar to that of glucose. A controlling role or phosphorylase in the regulation of glycogen metabolism by glucose is supported. Although the existence and nature of an intracellular effector is as yet unknown, crystallographic analyses of phosphorylase a crystals soaked in perchloric acid extracts of liver demonstrate that the negative effector site binds a natural metabolite.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794883     DOI: 10.1139/o81-054

Source DB:  PubMed          Journal:  Can J Biochem        ISSN: 0008-4018


  6 in total

1.  Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

Authors:  W H Martin; D J Hoover; S J Armento; I A Stock; R K McPherson; D E Danley; R W Stevenson; E J Barrett; J L Treadway
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Authors:  Tracy P Torres; Noriyasu Sasaki; E Patrick Donahue; Brooks Lacy; Richard L Printz; Alan D Cherrington; Judith L Treadway; Masakazu Shiota
Journal:  J Pharmacol Exp Ther       Date:  2011-03-01       Impact factor: 4.030

3.  Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor.

Authors:  D Massillon; W Stalmans; G van de Werve; M Bollen
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

4.  Stimulation of glycogenolysis in isolated hepatocytes by adenosine and one of its analogues is inhibited by caffeine.

Authors:  J C Stanley; J Markovic; A M Gutknecht; F J Lozeman
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

5.  Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes.

Authors:  Theodore Latsis; Birgitte Andersen; Loranne Agius
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

6.  Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty rats.

Authors:  Tracy P Torres; Yuka Fujimoto; E P Donahue; Richard L Printz; Karen L Houseknecht; Judith L Treadway; Masakazu Shiota
Journal:  Diabetes       Date:  2011-07-19       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.